Oncological outcomes of testicular cancer patients: 10 years of experiences resulting from a single university-based hospital

[1] Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, et al. Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urol. 2019 Aug;202(2):272–281. StephensonA EggenerSE BassEB ChelnickDM DaneshmandS FeldmanD Diagnosis and treatment of early stage testicular cancer: AUA guideline J Urol 2019 Aug 202 2 272 281 10.1097/JU.000000000000031831059667 Search in Google Scholar

[2] https://gco.iarc.fr/today/data/factsheets/populations/764-thailand-fact-sheets.pdf. (date accessed: September 26, 2021). https://gco.iarc.fr/today/data/factsheets/populations/764-thailand-fact-sheets.pdf (date accessed: September 26, 2021). Search in Google Scholar

[3] Hanna NH, Einhorn LH. Testicular cancer – discoveries and updates. N Engl J Med. 2014 Nov 20;371(21):2,005–16. HannaNH EinhornLH Testicular cancer – discoveries and updates N Engl J Med 2014 Nov 20 371 21 2,005 16 10.1056/NEJMra140755025409373 Search in Google Scholar

[4] Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. European Association of Urology. guidelines on testicular cancer: 2015 update. Eur Urol. 2015 Dec;68(6):1,054–68. AlbersP AlbrechtW AlgabaF BokemeyerC Cohn-CedermarkG FizaziK European Association of Urology. guidelines on testicular cancer: 2015 update Eur Urol 2015 Dec 68 6 1,054 68 10.1016/j.eururo.2015.07.04426297604 Search in Google Scholar

[5] Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. European Association of Urology. guidelines on testicular cancer: 2015 update. Eur Urol. 2015 Dec;68(6):1,054–68. AlbersP AlbrechtW AlgabaF BokemeyerC Cohn-CedermarkG FizaziK European Association of Urology. guidelines on testicular cancer: 2015 update Eur Urol 2015 Dec 68 6 1,054 68 10.1016/j.eururo.2015.07.044 Search in Google Scholar

[6] Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol. 2018 Aug 1;29(8):1,658–1,686. HoneckerF AparicioJ BerneyD BeyerJ BokemeyerC CathomasR ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up Ann Oncol 2018 Aug 1 29 8 1,658 1,686 10.1093/annonc/mdy21730113631 Search in Google Scholar

[7] Laguna M.P, Albers P. Albrech W, et al. EAU guidelines on testicular cancer. EAU; 2019. Available from: http://www.uroweb.org/guideline/testicular-cancer/. Accessed February 12, 2020. LagunaM.P AlbersP. AlbrechW EAU guidelines on testicular cancer EAU 2019 Available from: http://www.uroweb.org/guideline/testicular-cancer/. Accessed February 12, 2020. Search in Google Scholar

[8] Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. European Association of Urology. guidelines on testicular cancer: 2015 update. Eur Urol. 2015 Dec;68(6):1,054–68. AlbersP AlbrechtW AlgabaF BokemeyerC Cohn-CedermarkG FizaziK European Association of Urology. guidelines on testicular cancer: 2015 update Eur Urol 2015 Dec 68 6 1,054 68 10.1016/j.eururo.2015.07.044 Search in Google Scholar

[9] Cathomas R, Hartmann M, Krege S, Souchon R, Lorch A, Mayer F, et al. interdisziplinäre Arbeitsgruppe Hodentumore. Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie. 2011;34(1–2):59–64. CathomasR HartmannM KregeS SouchonR LorchA MayerF interdisziplinäre Arbeitsgruppe Hodentumore Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients Onkologie 2011 34 1–2 59 64 10.1159/00032334621346388 Search in Google Scholar

[10] Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, et al. International germ cell cancer classification update consortium. survival and new prognosticators in metastatic seminoma: results from the IGCCCG-Update Consortium. J Clin Oncol. 2021 May 10;39(14):1,553–1,562. doi: 10.1200/JCO.20.03292. Epub 2021 Mar 17. PMID: 33729863; PMCID: PMC8099394. BeyerJ ColletteL SauvéN DaugaardG FeldmanDR TandstadT International germ cell cancer classification update consortium. survival and new prognosticators in metastatic seminoma: results from the IGCCCG-Update Consortium J Clin Oncol 2021 May 10 39 14 1,553 1,562 10.1200/JCO.20.03292 Epub 2021 Mar 17. PMID: 33729863; PMCID: PMC8099394. 809939433729863 Open DOISearch in Google Scholar

[11] Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, et al. Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019 Dec;17(12):1,529–1,554. GilliganT LinDW AggarwalR ChismD CostN DerweeshIH Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology J Natl Compr Canc Netw 2019 Dec 17 12 1,529 1,554 10.6004/jnccn.2019.005831805523 Search in Google Scholar

[12] SEER cancer statistics factsheets: testicular cancer. National Cancer Institute. Bethesda, MD. 2019. date accessed: September 26, 2021. SEER cancer statistics factsheets: testicular cancer National Cancer Institute Bethesda, MD 2019 date accessed: September 26, 2021. Search in Google Scholar

[13] Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997 Jul 24;337(4):242–53. BoslGJ MotzerRJ Testicular germ-cell cancer N Engl J Med 1997 Jul 24 337 4 242 53 10.1056/NEJM1997072433704069227931 Search in Google Scholar

[14] Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, et al. American Society of Clinical Oncology. American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol. 2010 Jul 10;28(20):3,388–404. GilliganTD SeidenfeldJ BaschEM EinhornLH FancherT SmithDC American Society of Clinical Oncology. American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors J Clin Oncol 2010 Jul 10 28 20 3,388 404 10.1200/JCO.2009.26.448120530278 Search in Google Scholar

[15] Jack RH, Davies EA, Møller H. Testis and prostate cancer incidence in ethnic groups in South East England. Int J Androl. 2007 Aug;30(4):215–20; discussion 220–1. JackRH DaviesEA MøllerH Testis and prostate cancer incidence in ethnic groups in South East England Int J Androl 2007 Aug 30 4 215 20 discussion 220–1 10.1111/j.1365-2605.2007.00777.x17573844 Search in Google Scholar

[16] Purdue MP, Devesa SS, Sigurdson AJ, McGlynn KA. International patterns and trends in testis cancer incidence. Int J Cancer. 2005 Jul 10;115(5):822–7. PurdueMP DevesaSS SigurdsonAJ McGlynnKA International patterns and trends in testis cancer incidence Int J Cancer 2005 Jul 10 115 5 822 7 10.1002/ijc.2093115704170 Search in Google Scholar

[17] Biggs ML, Schwartz SM. Differences in testis cancer survival by race and ethnicity: a population-based study, 1973–1999 (United States). Cancer Causes Control. 2004 Jun;15(5):437–44. BiggsML SchwartzSM Differences in testis cancer survival by race and ethnicity: a population-based study, 1973–1999 (United States) Cancer Causes Control 2004 Jun 15 5 437 44 10.1023/B:CACO.0000036443.95995.4015286463 Search in Google Scholar

[18] Sadeghi M, Ghoncheh M, Mohammadian-Hafshejani A, Gandomani HS, Rafiemanesh H, Salehiniya H. Incidence and mortality of testicular cancer and relationships with development in Asia. Asian Pac J Cancer Prev. 2016;17(9):4,251–4,257. SadeghiM GhonchehM Mohammadian-HafshejaniA GandomaniHS RafiemaneshH SalehiniyaH Incidence and mortality of testicular cancer and relationships with development in Asia Asian Pac J Cancer Prev. 2016 17 9 4,251 4,257 Search in Google Scholar

[19] Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA. 2008 Feb 13;299(6):672–84. doi: 10.1001/jama.299.6.672. PMID: 18270356. FeldmanDR BoslGJ SheinfeldJ MotzerRJ Medical treatment of advanced testicular cancer JAMA 2008 Feb 13 299 6 672 84 10.1001/jama.299.6.672 PMID: 18270356. 18270356 Open DOISearch in Google Scholar

[20] Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987 Jun 4;316(23):1,435–40. doi: 10.1056/NEJM198706043162302. PMID: 2437455. WilliamsSD BirchR EinhornLH IrwinL GrecoFA LoehrerPJ Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide N Engl J Med 1987 Jun 4 316 23 1,435 40 10.1056/NEJM198706043162302 PMID: 2437455. 2437455 Open DOISearch in Google Scholar

[21] de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fosså SD, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001 Mar 15;19(6):1,629–40. doi: 10.1200/JCO.2001.19.6.1629. PMID: 11250991. de WitR RobertsJT WilkinsonPM de MulderPH MeadGM FossåSD Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council J Clin Oncol 2001 Mar 15 19 6 1,629 40 10.1200/JCO.2001.19.6.1629 PMID: 11250991. 11250991 Open DOISearch in Google Scholar

[22] Culine S, Kerbrat P, Kramar A, Théodore C, Chevreau C, Geoffrois L, et al. Genito-Urinary Group of the French Federation of Cancer Center (GETUG T93BP). Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007 May;18(5):917–24. CulineS KerbratP KramarA ThéodoreC ChevreauC GeoffroisL Genito-Urinary Group of the French Federation of Cancer Center (GETUG T93BP). Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP) Ann Oncol 2007 May 18 5 917 24 10.1093/annonc/mdm06217351252 Search in Google Scholar

[23] Fankhauser CD, Sander S, Roth L, Beyer J, Hermanns T. Improved survival in metastatic germ-cell cancer. Ann Oncol. 2018 Feb 1;29(2):347–351. FankhauserCD SanderS RothL BeyerJ HermannsT Improved survival in metastatic germ-cell cancer Ann Oncol 2018 Feb 1 29 2 347 351 10.1093/annonc/mdx74129161363 Search in Google Scholar

[24] Gillessen S, Sauvé N, Collette L, Daugaard G, de Wit R, Albany C, et al. International Germ Cell Cancer Classification Update Consortium. predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG Update Consortium. J Clin Oncol. 2021 May 10;39(14):1,563–1,574. GillessenS SauvéN ColletteL DaugaardG de WitR AlbanyC International Germ Cell Cancer Classification Update Consortium. predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG Update Consortium J Clin Oncol 2021 May 10 39 14 1,563 1,574 10.1200/JCO.20.03296809940233822655 Search in Google Scholar

[25] Nguyen MM, Ellison LM. Testicular cancer patterns in Asian-American males: an opportunity for public health education to impact outcomes. Urology. 2005 Sep;66(3):606–9. NguyenMM EllisonLM Testicular cancer patterns in Asian-American males: an opportunity for public health education to impact outcomes Urology 2005 Sep 66 3 606 9 10.1016/j.urology.2005.03.06916140087 Search in Google Scholar